Companies
Sherlock Biosciences
CRISPR diagnostics company licensed from Broad Institute — SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) for multiplexed rapid nucleic acid detection.
- Country
- United States
- Revenue
- ~$10M
- Employees
- ~60 emp
ISO 13485
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | 5 million diagnostic devices annually | sherlock.bio · cambridgeindependent.co.uk |
| Certification | ISO 13485-certified manufacturing facility | sherlock.bio · cambridgeindependent.co.uk |
| Regulatory approval | FDA Emergency Use Authorization (EUA) for SARS-CoV-2 (May 2020) | axelkra.us |
| Production site | Swavesey, UK (Buckingway Business Park) | orasure.com · sherlock.bio · cambridgeindependent.co.uk |
| Headcount | Approximately 45 employees at the UK facility as of 2023; total workforce 60+ as of acquisition medium confidence | cambridgeindependent.co.uk · sherlock.bio |
| Revenue | Primarily grant revenues for research and development purposes as of Dec 2024 | sec.gov |
Independent sources: axelkra.us · cambridgeindependent.co.uk · orasure.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| CRISPR diagnostics | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.